| KLAC |
Report |
Revenue (FQ4'26, June qtr) |
BEAT |
pred ~$3.66B vs. cons ~$3.60B |
MEDIUM |
| KLAC |
Report |
Non-GAAP EPS (FQ4'26) |
BEAT |
pred ~$10.20 vs. cons ~$9.90 |
MEDIUM |
| KLAC |
Report |
Non-GAAP gross margin (FQ4'26) |
IN-LINE |
pred ~62.1% vs. cons 61.75% |
MEDIUM |
| KLAC |
Guide |
Revenue guide (FQ1'27, Sept qtr) |
BETTER |
guide ~$3.85B vs. cons ~$3.75B (Sept-2026 qtr) |
MEDIUM |
| KLAC |
Guide |
Non-GAAP EPS guide (FQ1'27) |
BETTER |
guide ~$10.60 vs. cons ~$10.30 (Sept-2026 qtr) |
MEDIUM |
| KLAC |
Guide |
CY2027 growth framework (WFE/KLA yoy) |
UNKNOWN |
guide ~'higher than CY26 high-teens' (i.e. >18%) vs. cons ~15% (CY2027) |
LOW |
| KLAC |
Guide |
CY2026 gross-margin anchor |
UNCHANGED |
guide ~62% ±50bp vs. cons ~62% (CY2026) |
MEDIUM |
| KLAC |
Guide |
Advanced-packaging process-control revenue |
BETTER |
guide ~$1.05B vs. cons ~$1.0B (CY2026) |
LOW |
| KLAC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
LOW |
| KLAC |
Return |
5-day cumulative residual |
+4.5% (FOLLOW-THROUGH) |
Base case is a beat-and-raise into a stock that already gave back ~a third from its June-30 ($301.71) peak to $203.40, so positioning is de-risked. If the Sept-quarter guide confirms back-half CY26 acceleration and management reiterates/quantifies '2027 > 2026' plus another advanced-packaging up-revision, out-period estimates get revised UP, supporting follow-through. Risk is the nervous AI-capex/China-indigenization tape (TXN-style 'sell the beat'); given extreme realized vol (implied move ~8-10%) both magnitude and direction are low-confidence, and any hedged 2027/China language would flip this to a fade. |
LOW |